Literature DB >> 8005664

Induction of tumor necrosis factor alpha by the group- and type-specific polysaccharides from type III group B streptococci.

G Mancuso1, F Tomasello, C von Hunolstein, G Orefici, G Teti.   

Abstract

Previous studies suggested that circulating tumor necrosis factor alpha (TNF-alpha) may have a pathophysiologic role in experimental neonatal sepsis induced by group B streptococci (GBS). This study was undertaken to investigate the ability of the type III and group-specific polysaccharides of GBS to induce TNF-alpha production and TNF-alpha-dependent lethality in neonatal rats. The cytokine was detected in plasma samples by the L929 cytotoxicity assay. Intracardiac injections of either polysaccharide induced dose-dependent, transient elevations in plasma TNF-alpha levels that returned to baseline values after 5 h. The group-specific antigen induced significantly higher mean peak TNF-alpha levels than the type III antigen (125 +/- 47 versus 44 +/- 15 U/ml with 70 mg/kg of body weight). Glycogen (70 mg/kg), used as a negative control, did not induce TNF-alpha. The lipopolysaccharide-neutralizing agent polymyxin B did not decrease TNF-alpha levels induced by either polysaccharide, ruling out contamination with endotoxin as a possible cause of TNF-alpha induction. Fifty percent lethal doses of the type III and group-specific antigens given as intracardiac injections were 105 and 16 mg/kg, respectively. Salmonella endotoxin, used as a positive control, had a 50% lethal dose of 0.1 mg/kg. The lethal activities of GBS polysaccharides, as well as endotoxin, were completely prevented by pretreatment of neonatal rats with the respective specific antibodies or anti-murine TNF-alpha serum. To assess the relative importance of the type-specific substance in TNF-alpha induction by whole bacteria, two unrelated GBS transposon mutants devoid of only the type-specific capsular polysaccharide (COH1-13 and COH31-15) were employed. Each of the heat-killed unencapsulated mutants was able to produce plasma TNF-alpha level elevations or TNF-alpha-dependent lethality but was significantly less efficient in these activities than the corresponding encapsulated wild-type strain. These data suggest that the presence of type-specific material on GBS is not necessary for the stimulation of TNF-alpha production. Type III capsular polysaccharide, however, can significantly increase the ability of GBS to induce TNF-alpha. Further studies will be needed to assess the importance of TNF-alpha induction by the group- and type-specific antigens in the pathophysiology of GBS disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005664      PMCID: PMC302877          DOI: 10.1128/iai.62.7.2748-2753.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence.

Authors:  C E Rubens; M R Wessels; L M Heggen; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

2.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

3.  Effect of group B streptococcal type-specific antigen on polymorphonuclear leukocyte function and polymorphonuclear leukocyte-endothelial cell interaction.

Authors:  T L McFall; G A Zimmerman; N H Augustine; H R Hill
Journal:  Pediatr Res       Date:  1987-06       Impact factor: 3.756

4.  Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury.

Authors:  K E Stephens; A Ishizaka; J W Larrick; T A Raffin
Journal:  Am Rev Respir Dis       Date:  1988-06

5.  Induction by toxic-shock-syndrome toxin-1 of a circulating tumor necrosis factor-like substance in rabbits and of immunoreactive tumor necrosis factor and interleukin-1 from human mononuclear cells.

Authors:  T Ikejima; S Okusawa; J W van der Meer; C A Dinarello
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

6.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

7.  Human recombinant tumor necrosis factor alpha infusion mimics endotoxemia in awake sheep.

Authors:  J Johnson; B Meyrick; G Jesmok; K L Brigham
Journal:  J Appl Physiol (1985)       Date:  1989-03

8.  A group B streptococcal extract reduces neutrophil counts and induces neutrophil aggregation.

Authors:  T A Olson; G W Fischer; V G Hemming; W F O'Brien; S M Golden; D A Maybee
Journal:  Pediatr Res       Date:  1987-04       Impact factor: 3.756

9.  Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis.

Authors:  R G Titus; B Sherry; A Cerami
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

10.  Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens.

Authors:  R C Lancefield; M McCarty; W N Everly
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

View more
  21 in total

1.  Actinobacillus actinomycetemcomitans serotype b-specific polysaccharide antigen stimulates production of chemotactic factors and inflammatory cytokines by human monocytes.

Authors:  N Yamaguchi; Y Yamashita; D Ikeda; T Koga
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Human monocyte receptors involved in tumor necrosis factor responses to group B streptococcal products.

Authors:  M Cuzzola; G Mancuso; C Beninati; C Biondo; C von Hunolstein; G Orefici; T Espevik; T H Flo; G Teti
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 3.  Interaction of neonatal phagocytes with group B streptococcus: recognition and response.

Authors:  Philipp Henneke; Reinhard Berner
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  Soluble antigens from group B streptococci induce cytokine production in human blood cultures.

Authors:  C von Hunolstein; A Totolian; G Alfarone; G Mancuso; V Cusumano; G Teti; G Orefici
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

5.  Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis.

Authors:  L Tissi; M Puliti; R Barluzzi; G Orefici; C von Hunolstein; F Bistoni
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 6.  Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis.

Authors:  B Henderson; S Poole; M Wilson
Journal:  Microbiol Rev       Date:  1996-06

7.  Lectin microarray reveals binding profiles of Lactobacillus casei strains in a comprehensive analysis of bacterial cell wall polysaccharides.

Authors:  Emi Yasuda; Hiroaki Tateno; Jun Hirabayashi; Jun Hirabarashi; Tohru Iino; Tomoyuki Sako
Journal:  Appl Environ Microbiol       Date:  2011-05-20       Impact factor: 4.792

8.  Progressive Control of Streptococcus agalactiae-Induced Innate Inflammatory Response Is Associated with Time Course Expression of MicroRNA-223 by Neutrophils.

Authors:  Maud Deny; Marta Romano; Olivier Denis; Georges Casimir; Mustapha Chamekh
Journal:  Infect Immun       Date:  2020-11-16       Impact factor: 3.441

9.  The capsular polysaccharide complex of Bacteroides fragilis induces cytokine production from human and murine phagocytic cells.

Authors:  F C Gibson; A O Tzianabos; A B Onderdonk
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

10.  Adherence to, invasion by, and cytokine production in response to serotype VIII group B Streptococci.

Authors:  Hiroshige Mikamo; Atul K Johri; Lawrence C Paoletti; Lawrence C Madoff; Andrew B Onderdonk
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.